Answers are grounded in this paper and cite their sources.
A cost-effective, non-occlusive transcatheter aortic valve implantation (TAVI) deployment-system for non-calcific aortic valve disease: proof of concept During the past decade TAVI has revolutionized the approach to heart valve disease. Its role as a treatment modality for calcific degenerative aortic valve disease has been firmly established and continues to expand as the technology improves. More and more patients suffering from calcific valve stenosis now benefit from this less invasive treatment option. However, this latest trend towards ever-more sophisticated devices, which are associated with continually increasing demands on skills and equipment, has widened the gulf between high-income countries and the rest of the world. Unfortunately, this follows a vicious cycle: many more patients require valve surgery in low- to middle-income countries than in the industrialized world, but the limited economic power deprives patients in poorer countries from having sufficient access to tertiary cardiac services1. Apart from a seriously limited access to cardiac surgery itself, commercially available replacement heart valves, and to a certain degree repair procedures, are ill-suited for the largely young patients in need of life saving operations. Yet, this absence of a lucrative market has led to indifference towards solutions that take the different pathology and the constraint resources of these countries into consideration. Operating at the interface of the industrialized and the developing world, we came to believe that, counter intuitively, trans-catheter technologies may hold the key to cost effective heart valve surgery in low- to middle-income countries through recognizing the potential of their more widely available secondary hospitals. The thousands of lives of patients with critical mitral stenosis, that were saved by a trans-apically inserted Tubbs dilator, in the hands of general surgeons, gives testimony to the feasibility of such an approach, provided it takes the specific demands of the very different underlying pathology into account and can succeed within the comfort zone of general surgical skills. Crucially, the avoidance of tertiary cardiology support in by means of a simplified, slow and non-occlusive deployment provides one essential corner stone of such an approach. Tactile feedback rather than highly sophisticated dependence on imaging technology would need to be another. Whilst calcific aortic valve disease remains the dominant underlying pathology for patients in need of a heart valve replacement in the first world, rheumatic heart disease (RHD) still accounts for the majority of patients in need of a heart valve intervention in the developing world. Sliwa et al. found the incidence of RHD in >14-year-old South African patients still as high as 24/100 000 per year, a stark contrast to the <1/100 000 in developed countries2,3. More importantly, within 30 months of diagnosis, 22% of these newly diagnosed patients needed heart valve surgery2. It is estimated that in Africa alone there are 15 million patients living with RHD, of which 100 000 per year may need a heart valve intervention during some stage of their lives4. In our own experience, rheumatic heart disease accounts as the underlying pathology in more than 50% of patients requiring an isolated aortic valve replacement. (A) Calcific aortic valve disease. Placement of a transcatheter aortic valve implantation (TAVI) prosthesis typically relies on the fluoroscopic landmarks inherent to the underlying disease. (B) Non-calcific (‘compliant’) aortic valve disease. Absence of fluoroscopic landmarks requires alternative solutions for optimal positioning of a TAVI prosthesis. We therefore addressed the issue of location in the absence of a hydroxyapatite footprint, sophisticated imaging equipment through a self-homing, non-occlusive deployment system that is based on tactile feed-back. As this also applies to the potential need of pre- or post-dilatation of stenotic valves, the requirement for a non-occlusive balloon suggested a balloon-expandable TAVI system. The issue of non-calcific pathology in the presence of compliant aortic roots has been addressed by a self-anchoring stent design, and the durability in young patients by the alternative use of decellularized pericardium or heparinized polymer leaflets. (A) Non-occlusive device with helical deployment balloon and retractable location trunks. (B) Polymeric transcatheter aortic valve implantation prosthesis before crimping (left) and after crimping and expansion, showing elevated expansion arms (right). Physiological aortic and ventricular pressures were maintained during the non-occlusive deployment of the novel self-locating balloon expandable polymeric transcatheter aortic valve implantation prosthesis. With further optimizations of the deployment system and the stent design since the acute tests, and chronic implant studies having now commenced, we have successfully concluded the proof-of-concept phase for a transcatheter system that could eventually offer hope for the millions of patients with rheumatic heart disease who have no access to cardiac surgery. Conflict of interest: D.B., D.F.W., and P.Z. are directors of Strait Access Technologies. C.O. and J.S. are consultants to Strait Access Technologies. References are available as supplementary material at European Heart Journal online.
No takes yet. Share an insight, caveat, or question.
Scherman et al. (2017) studied Non-calcific aortic valve disease and rheumatic heart disease. Self-locating, non-occlusive balloon-expandable polymeric transcatheter aortic valve implantation (TAVI) system was evaluated on Maintenance of physiological aortic and ventricular pressures during non-occlusive deployment.
Synapse has enriched 10 related papers. Consider them for comparative context: